Managing Antiplatelet Therapy in Patients with Acute Coronary Syndrome

Published Online: Monday, March 25, 2013
Follow Pharmacy_Times:
In this podcast, Toby Trujillo, PharmD, BCPS, an associate professor at the University of Colorado Denver School of Pharmacy, discusses issues related to options for managing antiplatelet therapy in patients with acute coronary syndrome. To listen to the podcast, click here.
Related Articles
Patients who receive statins soon after acute coronary syndrome are 24% less likely to experience unstable angina after 4 months.
Patients continue to benefit from high-dose atorvastatin therapy for at least 5 years after acute coronary syndrome, according to a new study.
Study finds that black patients who visit the emergency department with ACS have more symptoms and higher symptom severity than white patients.
A recent study examines the comparative efficacy of prasugrel and clopidogrel in the treatment of patients who underwent percutaneous coronary intervention.
Latest Issues
$auto_registration$